EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft

Charlotte Uro-Coste, Céline Lambert, Vincent Audard, Lionel Couzi iD, Sophie Caillard, Matthias Büchler, Arnaud Del Bello, Paolo Malvezzi, Vincent Pernin, Charlotte Colosio, Laurent Mesnard, Dominique Bertrand und 21 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfae108 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Charlotte Uro-Coste und 32 weiteren Autor:innen. Beteiligte Einrichtung: Service de Néphrologie, CHU Clermont-Ferrand, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Glomerulosclerosis, Focal Segmental, Graft Rejection, Kidney Failure, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrence of focal segmental glomerulosclerosis (FSGS) is common after kidney transplantation and is classically associated with a significant decrease in graft survival. A major risk factor is a prior history of FSGS recurrence on a previous graft. This analysis reports the impact of a prophylactic treatment of FSGS recurrence in very high-risk patients who experienced a recurrence on a previous graft.

Methods

We performed a retrospective multicentre observational study in 25 French transplantation centres. The inclusion criteria were patients aged more than 18 years who had undergone kidney transplant between 31 December 2004 and 31 December 2020, and who had a history of FSGS recurrence on a previous graft.

Results

We identified 66 patients: 40 received prophylactic treatment (PT+), including intravenous cyclosporine and/or rituximab and/or plasmapheresis, and 26 did not receive any prophylactic treatment (PT–). The time to progression to end-stage kidney disease was similar between groups. The PT+ group was younger at FSGS diagnosis and at the time of kidney retransplantation and lost their previous graft faster. The overall recurrence rate was 72.7% (76.9% in the PT– group and 70.0% in the PT+ group, P = .54). At least partial remission was achieved in 87.5% of patients. The 5-year graft survival was 67.7% [95% confidence interval (CI) 53.4%–78.4%]: 65.1% (95% CI 48.7%–77.4%) in patients with FSGS recurrence vs 77.3% (95% CI 43.8%–92.3%) in patients without recurrence (P = .48).

Conclusion

Our study suggests that prophylactic treatment should not be used routinely in patients receiving a second transplantation after recurrence of FSGS on a previous graft. The recurrence rate is high regardless of the use of prophylactic treatment. However, the 5-year graft survival remains satisfactory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationGlomerulosclerosis, Focal SegmentalGraft RejectionKidney Failure, ChronicImmunosuppressive AgentsHumansMaleRetrospective StudiesFemaleGraft SurvivalRecurrenceAdultMiddle AgedFollow-Up StudiesPrognosisRisk FactorsPlasmapheresis

Stichwörter der Autor:innen

focal segmental glomerulosclerosisgraft survivalkidney transplantationprophylactic treatmentrecurrent glomerular disease

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Service de Néphrologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Unité de Biostatistiques, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Assistance Publique des Hôpitaux de Paris, Service de Néphrologie et Transplantation Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Hôpitaux Universitaires Henri-Mondor, Univ Paris Est Créteil,…
  • Service de Néphrologie, Transplantation, Dialyse et Aphérèses, CHU de Bordeaux, Bordeaux, France.
  • Service de Néphrologie, University Hospital, Strasbourg, France.
  • Service de Néphrologie et Immunologie Clinique, CHRU de Tours, Tours, France.

ORCID-Profile: Lionel Couzi, Nicolas Maillard

Zitieren

APA

Uro-Coste, C., Lambert, C., Audard, V., Couzi, L., Caillard, S., Büchler, M., Del Bello, A., Malvezzi, P., Pernin, V., Colosio, C., Mesnard, L., Bertrand, D., Martinez, F., Ducloux, D., Poulain, C., Thierry, A., Danthu, C., Greze, C., Lanaret, C., …, & Garrouste, C. (2025). Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae108

Vancouver

Uro-Coste C, Lambert C, Audard V, Couzi L, Caillard S, Büchler M, et al. Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae108

BibTeX
@article{UroCoste2025,
  author = {Uro-Coste, Charlotte and Lambert, Céline and Audard, Vincent and Couzi, Lionel and Caillard, Sophie and Büchler, Matthias and Del Bello, Arnaud and Malvezzi, Paolo and Pernin, Vincent and Colosio, Charlotte and Mesnard, Laurent and Bertrand, Dominique and Martinez, Frank and Ducloux, Didier and Poulain, Coralie and Thierry, Antoine and Danthu, Clément and Greze, Clarisse and Lanaret, Camille and Moal, Valérie and Hertig, Alexandre and Dantal, Jacques and Legendre, Christophe and Chatelet, Valérie and Sicard, Antoine and Gosset, Clément and Maillard, Nicolas and Duveau, Agnès and Petit, Clémence and Kamar, Nassim and Heng, Anne-Elisabeth and Anglicheau, Dany and Garrouste, Cyril},
  title = {Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfae108}
}
Kostenlos starten →